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Ecteinascidin-743 (ET-743) is a novel anticancer drug that is
produced by the marine tunicate Ecteinascidia turbinata (Rinehart
et al, 1990; Guan et al, 1993; Jimeno et al, 1996). It is a carbinol-
amine containing antibiotic composed of three tetra-hydroiso-
quinoline subunits. According to an NMR-based model, ET-743
interacts with the minor groove of DNA and alkylates guanine at
the N2 position (Moore et al, 1997). Alkylations of guanines were
also demonstrated by evaluating the changes in electrophoretic
mobility of guanine-containing oligonucleotides reacting with
ET-743 occurring after washing with a denaturing sodium dodecyl
sulphate (SDS)-containing solution to remove drug molecules
reversibly bound to DNA (Pommier et al, 1996; Zewail-Foote and
Hurley, 1999). The novel structure, unique mechanism of inter-
action with DNA and the potent preclinical antitumour activity
observed against human cancers (Ghielmini et al, 1998; Valoti
et al, 1998), understandably makes this drug an attractive 
candidate for clinical investigation.
The results recently obtained in the phase I clinical trials are
very encouraging as some objective responses have been observed
for doses of ET-743 associated with manageable toxicity
(Cvitkovic et al, 1999; Rayan et al, 1999).
Considering the pharmacological and clinical interest in this
compound we have attempted to obtain cell lines resistant to
ET-743 by using two different protocols, 1 h exposure or 24 h
exposure, of the human ovarian cancer Igrov-1 cell line to better
understand the possible mechanism(s) of resistance for this drug.
In this paper we report the results of these studies and a detailed
characterization of the most resistant cellular clone.
MATERIALS AND METHODS
Cells and culture conditions
The human ovarian carcinoma Igrov-1 cell line was grown in
monolayer in RPMI-1640 medium supplemented with 10% fetal
calf serum, 1% glutamine 200 mm (Gibco Europe, Paisley, UK)
at 37°C in a humidified 5% carbon dioxile (CO2) atmosphere in
T25 cm2 tissue flasks (IWAKI, Bibby Sterilin, Staffordshire, UK)
(Bénard et al, 1985).
Igrov-1/ET-743 resistant cells were derived from the Igrov-1
cell line by stepwise selection with ET-743 (kindly supplied by
PharmaMar, S.A. Tres Cantos, Spain). The cells were treated for
10 months with increasing concentrations at short (1 h) or long
(24–48 h) exposure times, starting from 20 and 0.5 nM respec-
tively. The concentrations were increased by a factor ranging from
1.5 to 2. The maximal ET-743 concentration reached was 800 nM
and 70 nM for short and prolonged exposure protocols respec-
tively. The clonal subpopulations were obtained by isolating
individual colonies of Igrov-1 subline made resistant to ET-743 by
using the short exposure protocol. Briefly, cells were plated at
900 cells per 87-mm tissue culture Petri dish (IWAKI) in 10 ml of
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culture medium. The cells were grown until individual cells had
formed single colonies of approximately 50 cells. The colonies
were separately sub-cultured using cloning rings and transferred to
a single well of a 96-well plate. When the cells reached 90%
confluency they were sub-cultured into a single 48-well plate and
subsequently in a 25 cm2 flask. The cell line derived from clone 25
which was the most resistant to ET-743, Igrov-1/25 ET, was
cultured in medium in absence of ET-743.
Clonogenicity test
Resistance to ET-743 was evaluated using a standard clonogenic
assay. Exponentially growing Igrov-1 and Igrov-1/25 ET cells
were treated for 1 h with different concentrations of ET-743,
doxorubicin (dox), melphalan (L-PAM), etoposide (VP-16),
cisplatin (cis-DDP), Oxaliplatin, camptotecin (CPT) and N-
methyl-N-nitro-N-nitrosoguanosine (MNNG). After treatment,
cells were washed twice with phosphate-buffered saline (PBS).
Then 3000 control or treated cells were plated in 50-mm tissue
culture dishes with 3 ml fresh medium. The colonies were allowed
to develop for 10–14 days. Plating efficiency of the exponentially
growing control cells was between 40 and 50%. The colonies were
stained with 1% crystal violet solution in 20% ethanol, and the
number of colonies were measured using the Entry Level image
system (Immagini & Computer, Bareggio, Milan, Italy). A back-
ground correction was made and the smallest control cell colony
was taken as the minimum for setting the cut-off point.
To evaluate the modulation of ET-743 cytotoxicity by the mdr
phenotype reversing agent SDZ PSC-833 (PSC), both Igrov-1 and
Igrov-1/25 ET cell lines were treated with different concentrations
of ET-743 alone or in combination with 1 mM PSC for 1 h. The
cytotoxicity was evaluated by the colony previously described.
The analysis of variance, stratified by drug concentrations, was
performed to assess the differences in the dose–response curves.
Flow cytometric DNA, protein and cytokeratin content
DNA, protein and cytokeratin content of Igrov-1 and Igrov-1/25
ET cell line were evaluated by standard flow cytometric methods
(Broggini et al, 1988; Ferrero et al, 1990).
Flow cytometric analysis of multidrug-related proteins
Cells were detached from the tissue culture plates by trypsiniza-
tion, washed with PBS and then counted. Cells (106) were washed
with PBS and 2% human serum (HS) and incubated for 60 min
with 150 ml anti-P-glycoprotein (P-gp) antibody, clone MRK-16,
diluted 1:30 in PBS + 2% HS at room temperature in the dark
(Kamiya Biochemical, Seattle, WA, USA). Then the cells were
washed in PBS + 2% HS and incubated with a fluorescein isothio-
cyanate (FITC)-conjugated AffiniPure F(ab´)2 fragment goat anti-
mouse IgG (Jackson Immuno Research Lab. Inc., West Grove, PA,
USA) diluted 1:50 for 1 h at room temperature in the dark.
Multidrug resistance-associated protein (MRP) and lung resis-
tance-related protein (LRP) were evaluated in cells after permeabi-
lization in 1% (v/v) lysing solution G (Becton Dickinson, San
Jose, CA, USA) in dH2O and incubated for 10 min in PBS/BSA
containing 1% (v/v) normal goat serum (NGS). Cells (106) were
incubated for 1 h at 4°C in 150 ml antibody (anti-MRP and anti-
LRP, clone MRPr1 or clone LRP-56 respectively, diluted 1:30 in
PBS/BSA containing 1% NGS in the dark (Kamiya Biochemical).
Cells were washed in PBS/BSA + 1% NGS and incubated with a
FITC-conjugated AffiniPure F(ab´)2 fragment goat anti-rat IgG
1:100 for MRP or with a FITC-conjugated AffiniPure F(ab¢)2 frag-
ment goat anti-mouse IgG 1:50 for LRP (Kamiya Biochemical).
Cells were resuspended in PBS and the flow cytometry analyses
were performed on at least 20 000 cells for each sample by the
FacSort cytometry system (Becton Dickinson) (Krishan et al,
1997). Igrov-1, A2780, LoVo/DX and POGB/DX, kindly supplied
by Dr R Supino, Istituto Nazionale  dei Tumori, Milan (Binaschi et
al, 1995), were used as positive controls.
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Figure 1 (A) Effects of ET-743 on the clonogenicity of Igrov-1 parental cell
line (n n) and the two clones made resistant to ET-743 by step-wise increase
in drug concentration and by using either short (u u) or prolonged drug
exposure protocols (l l). Points are the mean of six independent replicates;
bars represent s.d. (B) Flow cytometric analysis of P-gp expression of Igrov-1
parental cell line (A) and of the two clones made resistant to ET-743 by step-
wise increase in drug concentration and by using either short (B) or
prolonged drug exposure protocols (C)1734 E Erba et al
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Flow cytometric studies of dox uptake and efflux
Exponentially growing Igrov-1 and Igrov-1/25 ET cells were incu-
bated for 4 h at 37°C in 5% CO2 with different concentrations of
dox. Then control and dox-treated cells were centrifugated at 4°C
and resuspended in new medium. At different time intervals during
dox incubation (uptake) and at 15, 30, 60, 120 and 240 min after
drug-washout (efflux), the total fluorescence was measured by
Facs Star Plus (Becton Dickinson). Dox fluorescence was detected
with excitation at 488 nm and emission above 530 nm. The
analyses were performed on at least 50 000 cells and the data are
the mean of three independent replicates. Dead cells were
excluded on the basis of their scatter signals. Measurements were
corrected for the contribution of fluorescence of untreated cells
(Limonta et al, 1991).
DNA blot analysis
Genomic DNA from cells was isolated according to standard
procedures and digested with EcoRI. Digested DNAs (25 mg) were
size fractioned on 0.8% gel agarose and transferred to nylon
membrane (Gene Screen Plus, NEN, Boston, MA, USA) as
described (Sambrook et al, 1989).
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Figure 2 (A) Effects of ET-743 on the clonogenicity of Igrov-1 parental cell line and the four clones obtained from Igrov-1 subline made resistant to ET-743 by
using the short drug exposure protocols. Points are the mean of six independent replicates; bars represent s.d. (n n) = Igrov-1; (u u) = Clone 9; (l l) = Clone 16;
(s s) = Clone 24; (: :) = Clone 25. (B) Flow cytometric analysis of P-gp expression of the four clones obtained from Igrov-1 subline made resistant to ET-743 by
using the short drug exposure protocols. In the histogram of Clone 25 the Igrov-1 parental cell line (first histogram on the left) is also shownIgrov-1 and Ecteinascidin-743 1735
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RNA blot analysis
Total cellular RNA was extracted by the guanidine isothio-
cyanate/caesium chloride centrifugation (Sambrook et al, 1989).
For Northern blot analysis 10 mg of total RNA was fractionated on
1% agarose gel containing 6.7% formaldehyde and transferred 
to nylon membrane (Gene Screen Plus). LoVo/DX mRNA was 
used as positive control (Broggini et al, 1988). Levels of gene
amplification or mRNA expression were determined by densitom-
etry of the autoradiograms. To normalize the amounts of loaded
DNA or RNA, the slot blots were rehybridized with a b-actin
probe.
Hybridization
The filters were pretreated for at least 1 h at 42°C in 50%
formamide, 10% dextran sulphate, 1 M sodium chloride, 1% SDS
and then hybridized overnight in the same mixture containing 
100 mg ml–1 of denaturated salmon sperm DNA and 1 ´ 106 cpm
ml–1 of [a-  32P] d-CTP labelled probes. Labelled probes were
obtained using the Rediprime Kit (Amersham Italia S.r.1., Milan,
Italy) utilizing the 1.3 Kb EcoRI-Sal1 insert of human mdr-1 gene
(pc Dr 1.3) and the 1.3 Kb Pst1 insert of the murine a-actin gene.
After hybridization, the membranes were washed twice at room
temperature in 2 ´ SSC (1 ´ SSC is 0.15 M sodium chloride–0.015
M sodium citrate) and once at 65°C in 2 ´ SSC and 1% SDS and
then exposed to Kodak XRP film at –80°C with an intensifying
screen.
RESULTS
Selection and characterization of cells
Figure 1A shows the effect of ET-743 on the clonogenicity of
Igrov-1 and of the two sublines made resistant to ET-743 by step-
wise increase in drug concentration and by using either prolonged
(l l) or short drug exposure protocols (u u). Both cell lines
expressed the multi-drug resistance protein P-gp assessed by using
the monoclonal antibody MRK16 (Figure 1B).
From Igrov-1 subline made resistant by using the short exposure
protocol 30 subclones were isolated and all were found to express
Pgp.
Out of these 30 clones we selected four clones to investigate the
cytotoxicity of ET-743 by clonogenic assay (Figure 2A). The IC50
of the four clones varied markedly in spite of the fact that the level
of the P-gp expression appeared to be similar in the different
clones, being the means fluorescence channel 316, 339, 334 and
454 in the clones 25, 16, 24 and 9 respectively (Figure 2B). We
then selected clone 25 (Igrov-1/25 ET) for further characterization
because it was the most resistant to ET-743.
In order to evaluate if the increased P-gp expression was due to
the amplification of mdr-1 gene and/or to increased mRNA levels
Southern and Northern blots analyses were carried out. No ampli-
fication of the mdr-1 gene was found (Figure 3A). A threefold
increase in the mRNA levels in the Igrov-1/25 ET cell line with
respect to the parental cell line was detected by densitometric
analysis (Figure 3B). These data indicate that the increased expres-
sion of P-gp was due to an increase in the level of mRNA of
mdr-1 gene and not to amplification of mdr-1 gene.
Morphology and growth characteristics of Igrov-1/25 ET cell
line were consistent with the parental Igrov-1 cell line. Igrov-1 and
Igrov-1/25 ET cell lines did not differ with respect to doubling
times, about 23 h for both, immunostaining of total protein or
cytokeratin content. Flow cytometric analysis showed that in both
Igrov-1 and Igrov-1/25 ET cell lines ET-743 caused a dramatic
block in G2 phase that was evident at concentrations of 20 and 
200 nM respectively. DNA content analysis showed in Igrov-1/25
ET cell line the appearance of a new cell population containing
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Figure 3 (A) Southern blotting analysis in Igrov-1 and Igrov-1/25 ET cells.
Serial dilution of DNA obtained from both cell lines were digested with EcoRI
and separated on agarose gel. Hybridization with mdr-1 probe and carried out
as described in Materials and methods. (B) mRNA levels of the mdr-1 gene in
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Figure 5 Flow cytometric analysis of P-gp, MRP and LRP expression in Igrov-1/25 ET (A), Igrov-1 (B), A2780 (C), LoVo/DX (D) and POGB/DX (E). Thin black
line: negative control, w/o addition of specific antibody; bold black line: cell line with addition of specific antibodytetraploid DNA (Figure 4). The resistance of Igrov-1/25 ET cell
line to ET-743 was stable over 24 months in absence of ET-743.
Expression of MRP and LRP
The expression of other proteins reported to be overexpressed in
multidrug-resistant cells such as MRP and LRP has been investi-
gated in Igrov-1/25 ET cell line in comparison with the parental
Igrov-1 cell line. As shown in Figure 5 there is a small comparable
expression of MRP and LRP in both Igrov-1/25 ET (Figure 5A)
and Igrov-1 (Figure 5B) cell lines. The expression of P-gp was
instead very marked in Igrov-1/25 ET cell line and undetectable in
Igrov-1 cell line. In the same figure the results obtained in other
cell lines used as positive control for MRP (i.e. A2780 cells,
Figure 5C) or P-gp (i.e. Lovo/DX cells (Figure 5D) POGB/DX
cells, Figure 5E) or MRP, LRP and Pgp (i.e. POGB/DX,
Figure 5E) are also shown.
Igrov-1 and Ecteinascidin-743 1737
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Figure 7 Flow cytometric determination of doxorubicin uptake and efflux on
Igrov-1/25 ET (s) and Igrov-1 parental (n). Each point is the mean of three
independent replicates. Standard deviation was less than 10%
Figure 8 Modulation of the clonogenic inhibitory effect of ET-743 by 1 mM
PSC on Igrov-1 parental and Igrov-1/25 ET cell lines. Points are the mean of
six independent replicates; bars represent s.d. (l l) = Igrov-1 treated with 
ET-743 alone; (l) = Igrov-1 treated with ET-743 plus PSC;
(n n) = Igrov-1/25 ET treated with ET-743 alone; (n) = Igrov-1/25 ET treated
with ET-743 plus PSCCross-resistance pattern
As shown in Figure 6, a 50-fold increase in the ET-743 concentra-
tions was required to cause a 50% reduction in the clonogenic
potential of Igrov-1/25 ET cell line compared to sensitive Igrov-1
parental cell line. A comparable degree of cross-resistance was
also found for dox and VP-16, while Igrov-1/25 ET cell line
remained equally sensitive to L-PAM, MNNG and CPT. The
sensitivity of Igrov-1/25 ET to cis-DDP and Oxaliplatin was
slightly less than that of the parental cell line. This difference
although small was statistically significant (P < 0.01).
Dox uptake and efflux
Figure 7 shows the curves of uptake and efflux of dox in Igrov-
1/25 ET and Igrov-1 cell lines. Dox uptake appeared to be slower
in Igrov-1/25 ET than in Igrov-1 parental cell lines. At 4 h incuba-
tion the intracellular dox level reached similar values in both
Igrov-1/25 ET and Igrov-1 cell lines. When dox was removed a
very rapid drug efflux in the Igrov-1/25 ET was observed. At 480
min the mean fluorescence value was only 10% less than the
maximal level reached at the end of treatment in Igrov-1 cell line,
whereas it was about 50% less in Igrov-1/25 ET cell line.
Reversal of resistance
PSC, a non-immunosuppressive cyclosporin derivative, is a potent
agent used to reverse MDR associated with the overexpression of
P-gp. In this study PSC was used at the subtoxic concentration of 1
mM in combination with ET-743. Figure 8 shows that PSC was able
to reverse resistance to ET-743: in Igrov-1/25 ET cells the IC50
values decreased from > 350 nM for ET-743 alone to < 50 nM for
the PSC and ET-743 combination. No differences were observed
in the Igrov-1 parental cell line when the clonogenic assay was
performed with or without PSC.
DISCUSSION
The present study shows that one of the mechanisms of resistance
to the anticancer drug ET-743 is related to the overexpression of
P-gp. Previous studies by this laboratory had shown that LoVo/DX
cells resistant to dox because of the overexpression of P-gp were
much less sensitive to ET-743 (Erba et al, 1996), indicating that
ET-743 is a substrate for P-gp. The present study shows that both
prolonged exposure with low ET-743 concentrations or short drug
exposure with relatively high concentration results in the selection
of resistant clones which overexpress mdr-1 gene. The clone that
we have characterized in detail, from which we derived the cell
line Igrov-1/25 ET, shows a typical behaviour of P-gp over-
expressing cells. It is cross-resistant to dox and VP16, but not to
alkylating agents, cis-DDP, Oxaliplatinum and CPT. We have not
evaluated the intracellular concentration of ET-743 in Igrov-1 and
Igrov-1/25 ET since the high potency of the drug would require an
extremely sensitive analytical method or labelled compound,
neither of which is available in our laboratory. The expression of
P-gp in Igrov-1/25 ET cells suggested that the resistance is
presumably related to a lower intracellular drug concentration.
We have verified this by evaluating dox which could be easily
estimated by determining the intracellular levels of fluorescence.
These experiments indicated that dox efflux was much more
efficient from Igrov-1/25 ET than from Igrov-1. It may be
presumed that a similar change in the cellular pharmacokinetic of
ET-743 is responsible for the resistance to this drug in Igrov-1/25
ET cells. This hypothesis is also supported by the fact that the
cyclosporine analogue PSC, which is a potent mdr-1 reversing
agent, could almost completely restore the sensitivity of Igrov/25
ET to ET-743 (Boesch et al, 1991).
Recently, Jin et al reported some preliminary data on the inhibi-
tion of the transcription of mdr-1 gene by ET-743 (Jin et al, 1999).
The effect appeared due to the ability of ET-743 to inhibit the
binding of the transcription factor NFY to a CCAAT box present
in the mdr-1 gene promoter. Whereas these data confirm previous
in vitro findings on the ability of ET-743 to prevent the formation
of the complex of NFY with its consensus DNA sequence
(Bonfanti et al, 1999) it is somehow surprising that by exposing
cells with ET-743 we obtained resistant cell lines which overex-
pressed mdr-1 gene.
It may be hypothesized that we have selected cell lines which
present alterations of the mechanism of regulation of the transcrip-
tion of mdr-1 gene which might be not dependent upon NFY
binding to the CCAAT box in the mdr-1 gene promoter. Future
studies will be directed to verify this hypothesis. The fact that PSC
can reverse the resistance to ET-743 can be of potential clinical
interest since this cyclosporine analogue is currently being investi-
gated with some other natural products which are also substrates
of P-gp such as anthracyclines, epipodophyllotoxins or taxanes. It
should be considered, however, that PSC might increase the
concentration of ET-743 in some P-gp expressing normal tissues
(e.g. liver), thus increasing its toxicity.
In order to evaluate the combination of ET-743 with reversing
agents in vivo we have already transplanted Igrov-1/25 ET in nude
mice and obtained a tumour which has maintained P-gp over-
expression. This model, once characterized, will be potentially
useful to identify new non-cross-resistant ET-743 analogue and 
to evaluate the efficacy of mdr-reversing agents to overcome 
ET-743 resistance.
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